The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1593
ISSUE1593
March 9, 2020
Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration
Download PDF: US English
Med Lett Drugs Ther. 2020 Mar 9;62(1593):40
Disclosures
Principal Faculty- Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
- Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
- Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
- F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report
Objective(s)
Upon completion of this activity, the participant will be able to:
- Describe the recently reported adverse effect associated with use of brolucizumab (Beovu) or treatment of macular degeneration.
We reviewed brolucizumab (Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue.1 On February 23, the American Society of Retina Specialists reported that 14 patients who received the drug have developed retinal vasculitis, a potentially vision-threatening complication.2
© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.
Previous article